安科生物(300009.SZ):獨家代理重組人卵泡刺激素-CTP融合蛋白注射液
格隆匯7月9日丨安科生物(300009.SZ)公佈,鑑於上海寶濟藥業股份有限公司(以下簡稱“寶濟藥業”)全資子公司蘇州晟濟藥業有限公司(以下簡稱“晟濟藥業”)自主開發的重組人卵泡刺激素-CTP融合蛋白注射液(以下簡稱“SJ02”或“協議產品”)即將上市,安徽安科生物工程(集團)股份有限公司(以下簡稱“公司”)及其全資子公司安徽安科醫藥有限公司(以下簡稱“安科醫藥”)與晟濟藥業於2025年7月9日達成合作,並簽署了《產品獨家代理協議》,公司及安科醫藥將獨家代理SJ02產品在中國大陸及港澳臺地區的銷售及營銷推廣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.